← Back to Clinical Trials
Recruiting NCT07518134

NCT07518134 A Study of Uveitis in Children <18 Years of Age

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07518134
Status Recruiting
Phase
Sponsor Jaeb Center for Health Research
Condition Uveitis
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2026-04-14
Primary Completion 2027-04

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 17 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2026-04-14 with a primary completion date of 2027-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to collect data regarding clinical features and current/past treatments in children under 18 with uveitis. The main questions it aims to answer are: * What are the frequency of uveitis subtypes in children? * What are clinical and demographic characteristics overall and within each type of uveitis? Participants will complete one enrollment visit with their doctor. Participants with uveitis onset \<6 months from enrollment date will also partake in a 12 month chart review.

Eligibility Criteria

Inclusion Criteria: * Age: * Incident cases (onset ≤ 6 months) \<17 years * Established cases (onset \> 6 months) \<18 years * Diagnosis of any type of uveitis (infectious or noninfectious) in any location except traumatic and post-operative uveitis. * Active or inactive uveitis with any treatment status (current / prior / none \[but under surveillance\]). Exclusion Criteria: * Bilateral uveitis with differing etiologies * Traumatic uveitis * Post-operative uveitis * Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is an investigative site personnel directly affiliated with this study or who is an employee of JAEB Center for Health Research. * Ocular disease related to Retinoblastoma, Coat's disease, retinitis pigmentosa, inherited retinal degeneration, Juvenile xanthogranuloma (JXG), or leukemia/malignancy within the eye.

Contact & Investigator

Central Contact

Julianne Zawadzki, MSPH

✉ jrobinson@jaeb.org

📞 813-975-8690

Principal Investigator

Kara C LaMattina, MD

STUDY CHAIR

Department of Ophthalmology, Boston University School of Medicine

Frequently Asked Questions

Who can join the NCT07518134 clinical trial?

This trial is open to participants of all sexes, up to 17 Years, studying Uveitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07518134 currently recruiting?

Yes, NCT07518134 is actively recruiting participants. Contact the research team at jrobinson@jaeb.org for enrollment information.

Where is the NCT07518134 trial being conducted?

This trial is being conducted at Boston, United States, Akron, United States, Cincinnati, United States, Columbus, United States.

Who is sponsoring the NCT07518134 clinical trial?

NCT07518134 is sponsored by Jaeb Center for Health Research. The principal investigator is Kara C LaMattina, MD at Department of Ophthalmology, Boston University School of Medicine. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology